|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Open-Angle Glaucoma | |||||
| 2 | Additional conditions recognized in this trial | ||||
| Glaucoma | |||||
| Glaucoma, Open-Angle | |||||
| 3 | More general conditions related to this trial | ||||
| Eye Diseases | |||||
| Ocular Hypertension | |||||
| 4 | Interventions listed in this trial | ||||
| Betaxolol | |||||
| Argon Laser Trabeculoplasty | |||||
| 5 | More general drug interventions related to this trial | ||||
| Adrenergic Agents | |||||
| Adrenergic Antagonists | |||||
| Adrenergic beta-Antagonists | |||||
| Antihypertensive Agents | |||||
| Autonomic Agents | |||||
| Cardiovascular Agents | |||||
| Molecular Mechanisms of Pharmacological Action | |||||
| Neurotransmitter Agents | |||||
| Peripheral Nervous System Agents | |||||
| Pharmacologic Actions | |||||
| Physiological Effects of Drugs | |||||
| Sympatholytics | |||||
| Therapeutic Uses | |||||
| 6 | Sponsors listed in this trial | ||||
| National Eye Institute (NEI) | |||||